Clinical Trial

A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma.This study includes a Phase Ia dose-escalation stage and a Phase Ib dose-expansion stage, and it is expected to take approximately 2 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Trial Details
NCT Number NCT07283796
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions NHL
Enrollment 110 participants
Start Date 2025-08-28
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-19